(PharmaNewsWire.Com, September 12, 2017 ) Migraine is a chronic neurovascular disorder characterized by severe recurrent headaches. It is one of the most common and most prevalent disabling neurological conditions, characterized by episodes often called migraine attacks. They are quite different from regular headaches which are non-migrainous. Migraineurs generally have a lower threshold to triggers that might cause neuronal hyperexcitability, including sleep disturbances, environmental or emotional challenges, alcohol exposure, diet, and hormonal cycles/changes, among others. Migraine attacks can cause significant pain for hours to days and can be so severe that the pain is disabling. Migraine headache is typically throbbing, unilateral (one sided) , and is aggravated by physical activity. It typically presents with additional symptoms in addition to headache pain, including nausea, and sensitivity to light and/or sound.
Depending on symptoms, migraine is broadly classified into two categories, Chronic and Episodic. Migraines can be treated with two types of drugs: abortive and preventive. Abortive medications are especially useful for people who have nausea or vomiting related to their migraine, and they work quickly. Preventive treatment is considered if migraine occurs frequently, typically more than one migraine per week, or if migraine symptoms are severe.
The global migraine market is set to experience favourable growth driven by factors such as increasing female population & increasing cigarette consumption. Further, the scope of growth for this market will be broadened by rising healthcare expenditure and accelerating economic growth. However, growth of this budding market will be hindered by limitations of current migraine therapies, regulatory challenges and high cost associated with migraine drugs.
The report "Global Migraine Market: Industry Analysis & Outlook (2017-2021) " analyses the development of this market, with focus majorly on the U.S. market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Amgen Inc., Eli Lilly and Company, Teva Pharmaceuticals & Alder Biopharmaceuticals are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global migraine market along with the study of the regional markets.
Table of Content: 1. Market Overview 2. Global Market Analysis 3. Regional Market 4. Market Dynamics 5. Competition 6. Company Profiles 6.1 Amgen Inc. 6.1.1 Business Overview 6.1.2 Financial Overview 6.1.3 Business Strategies 6.2 Eli Lilly and Company 6.2.1 Business Overview 6.2.2 Financial Overview 6.2.3 Business Strategies 6.3 Teva Pharmaceuticals 6.3.1 Business Overview 6.3.2 Financial Overview 6.3.3 Business Strategies 6.4 Alder Biopharmaceuticals 6.4.1 Business Overview 6.4.2 Financial Overview 6.4.3 Business Strategies Inquire for Report at http://www.reportsweb.com/inquiry&RW0001840432/discount
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: